CA Patent

CA3292509A1 — Manufacture of a crystalline pharmaceutical product

Assigned to Orion Oyj · Expires 2026-03-02 · 0y expired

What this patent protects

The present invention relates to crystalline particles of N-((S)-1-(3-(3-chloro-4- cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m2/g, preferably from about 10 …

USPTO Abstract

The present invention relates to crystalline particles of N-((S)-1-(3-(3-chloro-4- cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m2/g, preferably from about 10 to about 15 m2/g, and to the method for the preparation of such particles. Compound (I) is a potent androgen receptor (AR) modulator which is useful as a medicament for example in the treatment of prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3292509A1
Jurisdiction
CA
Classification
—
Expires
2026-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.